human breast cancer cell line  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    ATCC human breast cancer cell line
    Human Breast Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human breast cancer cell line/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human breast cancer cell line - by Bioz Stars, 2024-07
    93/100 stars

    Images

    crl 2326 hcc2218 atcc  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC crl 2326 hcc2218 atcc
    Crl 2326 Hcc2218 Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2326 hcc2218 atcc/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    crl 2326 hcc2218 atcc - by Bioz Stars, 2024-07
    86/100 stars

    Images

    human breast cancer cell line  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    ATCC human breast cancer cell line
    Human Breast Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human breast cancer cell line/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human breast cancer cell line - by Bioz Stars, 2024-07
    93/100 stars

    Images

    human breast cancer cell line bt 474  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    ATCC human breast cancer cell line bt 474
    ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.
    Human Breast Cancer Cell Line Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human breast cancer cell line bt 474/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human breast cancer cell line bt 474 - by Bioz Stars, 2024-07
    93/100 stars

    Images

    1) Product Images from "Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody"

    Article Title: Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody

    Journal: mAbs

    doi: 10.1080/19420862.2018.1486946

    ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.
    Figure Legend Snippet: ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.

    Techniques Used: Activity Assay

    hcc1419 crl 2326  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC hcc1419 crl 2326
    ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.
    Hcc1419 Crl 2326, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcc1419 crl 2326/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hcc1419 crl 2326 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody"

    Article Title: Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody

    Journal: mAbs

    doi: 10.1080/19420862.2018.1486946

    ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.
    Figure Legend Snippet: ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.

    Techniques Used: Activity Assay


    Structured Review

    Jackson Laboratory crl 2326 hmec myc er horiuchi
    Crl 2326 Hmec Myc Er Horiuchi, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2326 hmec myc er horiuchi/product/Jackson Laboratory
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    crl 2326 hmec myc er horiuchi - by Bioz Stars, 2024-07
    86/100 stars

    Images

    crl 2326 hmec myc er horiuchi  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC crl 2326 hmec myc er horiuchi
    Crl 2326 Hmec Myc Er Horiuchi, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2326 hmec myc er horiuchi/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    crl 2326 hmec myc er horiuchi - by Bioz Stars, 2024-07
    86/100 stars

    Images

    breast ductal carcinoma hcc1419  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    ATCC breast ductal carcinoma hcc1419
    SLMP53-2 inhibits the growth of mutp53-Y220C-expressing tumor cells with no genotoxicity, leading to the differential expression of genes involved in cell cycle and death, lipid metabolism, and endoplasmic reticulum (ER) stress. ( A ) Concentration-response curves for SLMP53-2 in human non-tumoral HFF-1 and tumor mutp53-Y220C-expressing HuH-7 and <t>HCC1419</t> cells, analyzed by sulforhodamine B (SRB) assay after 48 h treatment with 3.12–50 µM SLMP53-2. Data are mean ± SEM ( n = 5); * p < 0.05, extra sum-of-squares F test. ( B ) IC 50 values of SLMP53-2 and APR-246 in HuH-7 and HCC1419 cells were determined by SRB assay after 48 h treatment with 3.12–50 µM SLMP53-2 or APR-246. Data are mean ± SEM ( n = 5); * p < 0.05, two-way ANOVA with Sidak’s multiple comparison test. ( C ) Effect of SLMP53-2 in HuH-7 cell colony formation, analyzed after 14 days incubation with SLMP53-2; a representative experiment is shown. Data are mean ± SEM ( n = 5); values significantly different from DMSO: * p < 0.05, one-way ANOVA with Dunnett’s multiple comparison test. ( D ) Levels of γH2AX in HuH-7 cells treated with SLMP53-2; 50 µM etoposide was used as a positive control (PC). ( E ) Levels of mutp53 phosphorylation at Ser15 in HuH-7 cells treated with 14 µM SLMP53-2. In ( D , E ), immunoblots represent one of three independent experiments; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. ( F ) Top enriched biological pathways grouped by broad categories based on Ingenuity Pathway Analysis (IPA) starting from the dataset of differentially expressed genes (DEGs) from HuH-7 cells treated with 28 µM SLMP53-2. The number of features for each functional annotation is given in parenthesis. The score combines the log10 p -value and predicted pathway activation or repression status of the corresponding pathway/process, respectively for positive and negative score. The different colors correspond to the different functional annotation categories. ( G ) Top scoring upstream regulators inferred from the same gene expression dataset. The score is the log10 p -value of the predicted activation status. ( H ) Gene expression changes of NUPR1 (blue) and ATF4 (yellow) target genes in SLMP53-2-treated HuH-7 cells.
    Breast Ductal Carcinoma Hcc1419, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast ductal carcinoma hcc1419/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    breast ductal carcinoma hcc1419 - by Bioz Stars, 2024-07
    93/100 stars

    Images

    1) Product Images from "SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma"

    Article Title: SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma

    Journal: Cancers

    doi: 10.3390/cancers11081151

    SLMP53-2 inhibits the growth of mutp53-Y220C-expressing tumor cells with no genotoxicity, leading to the differential expression of genes involved in cell cycle and death, lipid metabolism, and endoplasmic reticulum (ER) stress. ( A ) Concentration-response curves for SLMP53-2 in human non-tumoral HFF-1 and tumor mutp53-Y220C-expressing HuH-7 and HCC1419 cells, analyzed by sulforhodamine B (SRB) assay after 48 h treatment with 3.12–50 µM SLMP53-2. Data are mean ± SEM ( n = 5); * p < 0.05, extra sum-of-squares F test. ( B ) IC 50 values of SLMP53-2 and APR-246 in HuH-7 and HCC1419 cells were determined by SRB assay after 48 h treatment with 3.12–50 µM SLMP53-2 or APR-246. Data are mean ± SEM ( n = 5); * p < 0.05, two-way ANOVA with Sidak’s multiple comparison test. ( C ) Effect of SLMP53-2 in HuH-7 cell colony formation, analyzed after 14 days incubation with SLMP53-2; a representative experiment is shown. Data are mean ± SEM ( n = 5); values significantly different from DMSO: * p < 0.05, one-way ANOVA with Dunnett’s multiple comparison test. ( D ) Levels of γH2AX in HuH-7 cells treated with SLMP53-2; 50 µM etoposide was used as a positive control (PC). ( E ) Levels of mutp53 phosphorylation at Ser15 in HuH-7 cells treated with 14 µM SLMP53-2. In ( D , E ), immunoblots represent one of three independent experiments; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. ( F ) Top enriched biological pathways grouped by broad categories based on Ingenuity Pathway Analysis (IPA) starting from the dataset of differentially expressed genes (DEGs) from HuH-7 cells treated with 28 µM SLMP53-2. The number of features for each functional annotation is given in parenthesis. The score combines the log10 p -value and predicted pathway activation or repression status of the corresponding pathway/process, respectively for positive and negative score. The different colors correspond to the different functional annotation categories. ( G ) Top scoring upstream regulators inferred from the same gene expression dataset. The score is the log10 p -value of the predicted activation status. ( H ) Gene expression changes of NUPR1 (blue) and ATF4 (yellow) target genes in SLMP53-2-treated HuH-7 cells.
    Figure Legend Snippet: SLMP53-2 inhibits the growth of mutp53-Y220C-expressing tumor cells with no genotoxicity, leading to the differential expression of genes involved in cell cycle and death, lipid metabolism, and endoplasmic reticulum (ER) stress. ( A ) Concentration-response curves for SLMP53-2 in human non-tumoral HFF-1 and tumor mutp53-Y220C-expressing HuH-7 and HCC1419 cells, analyzed by sulforhodamine B (SRB) assay after 48 h treatment with 3.12–50 µM SLMP53-2. Data are mean ± SEM ( n = 5); * p < 0.05, extra sum-of-squares F test. ( B ) IC 50 values of SLMP53-2 and APR-246 in HuH-7 and HCC1419 cells were determined by SRB assay after 48 h treatment with 3.12–50 µM SLMP53-2 or APR-246. Data are mean ± SEM ( n = 5); * p < 0.05, two-way ANOVA with Sidak’s multiple comparison test. ( C ) Effect of SLMP53-2 in HuH-7 cell colony formation, analyzed after 14 days incubation with SLMP53-2; a representative experiment is shown. Data are mean ± SEM ( n = 5); values significantly different from DMSO: * p < 0.05, one-way ANOVA with Dunnett’s multiple comparison test. ( D ) Levels of γH2AX in HuH-7 cells treated with SLMP53-2; 50 µM etoposide was used as a positive control (PC). ( E ) Levels of mutp53 phosphorylation at Ser15 in HuH-7 cells treated with 14 µM SLMP53-2. In ( D , E ), immunoblots represent one of three independent experiments; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. ( F ) Top enriched biological pathways grouped by broad categories based on Ingenuity Pathway Analysis (IPA) starting from the dataset of differentially expressed genes (DEGs) from HuH-7 cells treated with 28 µM SLMP53-2. The number of features for each functional annotation is given in parenthesis. The score combines the log10 p -value and predicted pathway activation or repression status of the corresponding pathway/process, respectively for positive and negative score. The different colors correspond to the different functional annotation categories. ( G ) Top scoring upstream regulators inferred from the same gene expression dataset. The score is the log10 p -value of the predicted activation status. ( H ) Gene expression changes of NUPR1 (blue) and ATF4 (yellow) target genes in SLMP53-2-treated HuH-7 cells.

    Techniques Used: Expressing, Concentration Assay, Sulforhodamine B Assay, Incubation, Positive Control, Western Blot, Functional Assay, Activation Assay

    breast ductal carcinoma hcc1419  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    ATCC breast ductal carcinoma hcc1419
    Breast Ductal Carcinoma Hcc1419, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast ductal carcinoma hcc1419/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    breast ductal carcinoma hcc1419 - by Bioz Stars, 2024-07
    93/100 stars

    Images

    breast ductal carcinoma hcc1419  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    ATCC breast ductal carcinoma hcc1419
    Breast Ductal Carcinoma Hcc1419, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast ductal carcinoma hcc1419/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    breast ductal carcinoma hcc1419 - by Bioz Stars, 2024-07
    93/100 stars

    Images

    hcc1419 crl 2326 ductal carcinoma  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC hcc1419 crl 2326 ductal carcinoma
    A panel of 12 parental and derived BCCLs were tested for trastuzumab response. Cells were classified as sensitive (S) or resistant (R) by testing cell proliferation in the presence and absence of 15 µg/ml trastuzumab for 7 days. Response to trastuzumab was quantified by calculating the fold change in the growth rate (∆GR) of the treated cells relative to the non-treated cells. In all cases resistance was defined as a response of ≤ 1.2 in growth rate
    Hcc1419 Crl 2326 Ductal Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcc1419 crl 2326 ductal carcinoma/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hcc1419 crl 2326 ductal carcinoma - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines"

    Article Title: Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines

    Journal: American Journal of Cancer Research

    doi:

    A panel of 12 parental and derived BCCLs were tested for trastuzumab response. Cells were classified as sensitive (S) or resistant (R) by testing cell proliferation in the presence and absence of 15 µg/ml trastuzumab for 7 days. Response to trastuzumab was quantified by calculating the fold change in the growth rate (∆GR) of the treated cells relative to the non-treated cells. In all cases resistance was defined as a response of ≤ 1.2 in growth rate
    Figure Legend Snippet: A panel of 12 parental and derived BCCLs were tested for trastuzumab response. Cells were classified as sensitive (S) or resistant (R) by testing cell proliferation in the presence and absence of 15 µg/ml trastuzumab for 7 days. Response to trastuzumab was quantified by calculating the fold change in the growth rate (∆GR) of the treated cells relative to the non-treated cells. In all cases resistance was defined as a response of ≤ 1.2 in growth rate

    Techniques Used: Derivative Assay

    Amplification signal of the HER2 gene as determined by FISH. BCCL that showed ratio > 2.0 and > 4 HER2 copies were labeled as amplified, and those cases with ratio < 2.0 and 4-6 HER2 copies were determined as equivocal. Heterogeneity was observed as the percentage of tumor cells with ratio < 2.0 and < 4 HER2 copies
    Figure Legend Snippet: Amplification signal of the HER2 gene as determined by FISH. BCCL that showed ratio > 2.0 and > 4 HER2 copies were labeled as amplified, and those cases with ratio < 2.0 and 4-6 HER2 copies were determined as equivocal. Heterogeneity was observed as the percentage of tumor cells with ratio < 2.0 and < 4 HER2 copies

    Techniques Used: Amplification, Labeling

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    ATCC human breast cancer cell line
    Human Breast Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human breast cancer cell line/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human breast cancer cell line - by Bioz Stars, 2024-07
    93/100 stars
      Buy from Supplier

    86
    ATCC crl 2326 hcc2218 atcc
    Crl 2326 Hcc2218 Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2326 hcc2218 atcc/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    crl 2326 hcc2218 atcc - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    93
    ATCC human breast cancer cell line bt 474
    ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.
    Human Breast Cancer Cell Line Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human breast cancer cell line bt 474/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human breast cancer cell line bt 474 - by Bioz Stars, 2024-07
    93/100 stars
      Buy from Supplier

    86
    ATCC hcc1419 crl 2326
    ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.
    Hcc1419 Crl 2326, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcc1419 crl 2326/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hcc1419 crl 2326 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Jackson Laboratory crl 2326 hmec myc er horiuchi
    ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.
    Crl 2326 Hmec Myc Er Horiuchi, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2326 hmec myc er horiuchi/product/Jackson Laboratory
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    crl 2326 hmec myc er horiuchi - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    ATCC crl 2326 hmec myc er horiuchi
    ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.
    Crl 2326 Hmec Myc Er Horiuchi, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2326 hmec myc er horiuchi/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    crl 2326 hmec myc er horiuchi - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    93
    ATCC breast ductal carcinoma hcc1419
    SLMP53-2 inhibits the growth of mutp53-Y220C-expressing tumor cells with no genotoxicity, leading to the differential expression of genes involved in cell cycle and death, lipid metabolism, and endoplasmic reticulum (ER) stress. ( A ) Concentration-response curves for SLMP53-2 in human non-tumoral HFF-1 and tumor mutp53-Y220C-expressing HuH-7 and <t>HCC1419</t> cells, analyzed by sulforhodamine B (SRB) assay after 48 h treatment with 3.12–50 µM SLMP53-2. Data are mean ± SEM ( n = 5); * p < 0.05, extra sum-of-squares F test. ( B ) IC 50 values of SLMP53-2 and APR-246 in HuH-7 and HCC1419 cells were determined by SRB assay after 48 h treatment with 3.12–50 µM SLMP53-2 or APR-246. Data are mean ± SEM ( n = 5); * p < 0.05, two-way ANOVA with Sidak’s multiple comparison test. ( C ) Effect of SLMP53-2 in HuH-7 cell colony formation, analyzed after 14 days incubation with SLMP53-2; a representative experiment is shown. Data are mean ± SEM ( n = 5); values significantly different from DMSO: * p < 0.05, one-way ANOVA with Dunnett’s multiple comparison test. ( D ) Levels of γH2AX in HuH-7 cells treated with SLMP53-2; 50 µM etoposide was used as a positive control (PC). ( E ) Levels of mutp53 phosphorylation at Ser15 in HuH-7 cells treated with 14 µM SLMP53-2. In ( D , E ), immunoblots represent one of three independent experiments; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. ( F ) Top enriched biological pathways grouped by broad categories based on Ingenuity Pathway Analysis (IPA) starting from the dataset of differentially expressed genes (DEGs) from HuH-7 cells treated with 28 µM SLMP53-2. The number of features for each functional annotation is given in parenthesis. The score combines the log10 p -value and predicted pathway activation or repression status of the corresponding pathway/process, respectively for positive and negative score. The different colors correspond to the different functional annotation categories. ( G ) Top scoring upstream regulators inferred from the same gene expression dataset. The score is the log10 p -value of the predicted activation status. ( H ) Gene expression changes of NUPR1 (blue) and ATF4 (yellow) target genes in SLMP53-2-treated HuH-7 cells.
    Breast Ductal Carcinoma Hcc1419, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast ductal carcinoma hcc1419/product/ATCC
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    breast ductal carcinoma hcc1419 - by Bioz Stars, 2024-07
    93/100 stars
      Buy from Supplier

    86
    ATCC hcc1419 crl 2326 ductal carcinoma
    A panel of 12 parental and derived BCCLs were tested for trastuzumab response. Cells were classified as sensitive (S) or resistant (R) by testing cell proliferation in the presence and absence of 15 µg/ml trastuzumab for 7 days. Response to trastuzumab was quantified by calculating the fold change in the growth rate (∆GR) of the treated cells relative to the non-treated cells. In all cases resistance was defined as a response of ≤ 1.2 in growth rate
    Hcc1419 Crl 2326 Ductal Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcc1419 crl 2326 ductal carcinoma/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hcc1419 crl 2326 ductal carcinoma - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    Image Search Results


    ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.

    Journal: mAbs

    Article Title: Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody

    doi: 10.1080/19420862.2018.1486946

    Figure Lengend Snippet: ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.

    Article Snippet: Human breast cancer cell line BT-474 (HTB-20), MDA-MB-175VII (HTB-25), SK-BR-3(HTB-30) and HCC1419(CRL-2326) are HER2-positive cell lines, which were obtained from the ATCC, and HCC1419 is trastuzumab-resistant human breast cancer cell line.

    Techniques: Activity Assay

    ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.

    Journal: mAbs

    Article Title: Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody

    doi: 10.1080/19420862.2018.1486946

    Figure Lengend Snippet: ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.

    Article Snippet: Human breast cancer cell line BT-474 (HTB-20), MDA-MB-175VII (HTB-25), SK-BR-3(HTB-30) and HCC1419(CRL-2326) are HER2-positive cell lines, which were obtained from the ATCC, and HCC1419 is trastuzumab-resistant human breast cancer cell line.

    Techniques: Activity Assay

    SLMP53-2 inhibits the growth of mutp53-Y220C-expressing tumor cells with no genotoxicity, leading to the differential expression of genes involved in cell cycle and death, lipid metabolism, and endoplasmic reticulum (ER) stress. ( A ) Concentration-response curves for SLMP53-2 in human non-tumoral HFF-1 and tumor mutp53-Y220C-expressing HuH-7 and HCC1419 cells, analyzed by sulforhodamine B (SRB) assay after 48 h treatment with 3.12–50 µM SLMP53-2. Data are mean ± SEM ( n = 5); * p < 0.05, extra sum-of-squares F test. ( B ) IC 50 values of SLMP53-2 and APR-246 in HuH-7 and HCC1419 cells were determined by SRB assay after 48 h treatment with 3.12–50 µM SLMP53-2 or APR-246. Data are mean ± SEM ( n = 5); * p < 0.05, two-way ANOVA with Sidak’s multiple comparison test. ( C ) Effect of SLMP53-2 in HuH-7 cell colony formation, analyzed after 14 days incubation with SLMP53-2; a representative experiment is shown. Data are mean ± SEM ( n = 5); values significantly different from DMSO: * p < 0.05, one-way ANOVA with Dunnett’s multiple comparison test. ( D ) Levels of γH2AX in HuH-7 cells treated with SLMP53-2; 50 µM etoposide was used as a positive control (PC). ( E ) Levels of mutp53 phosphorylation at Ser15 in HuH-7 cells treated with 14 µM SLMP53-2. In ( D , E ), immunoblots represent one of three independent experiments; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. ( F ) Top enriched biological pathways grouped by broad categories based on Ingenuity Pathway Analysis (IPA) starting from the dataset of differentially expressed genes (DEGs) from HuH-7 cells treated with 28 µM SLMP53-2. The number of features for each functional annotation is given in parenthesis. The score combines the log10 p -value and predicted pathway activation or repression status of the corresponding pathway/process, respectively for positive and negative score. The different colors correspond to the different functional annotation categories. ( G ) Top scoring upstream regulators inferred from the same gene expression dataset. The score is the log10 p -value of the predicted activation status. ( H ) Gene expression changes of NUPR1 (blue) and ATF4 (yellow) target genes in SLMP53-2-treated HuH-7 cells.

    Journal: Cancers

    Article Title: SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma

    doi: 10.3390/cancers11081151

    Figure Lengend Snippet: SLMP53-2 inhibits the growth of mutp53-Y220C-expressing tumor cells with no genotoxicity, leading to the differential expression of genes involved in cell cycle and death, lipid metabolism, and endoplasmic reticulum (ER) stress. ( A ) Concentration-response curves for SLMP53-2 in human non-tumoral HFF-1 and tumor mutp53-Y220C-expressing HuH-7 and HCC1419 cells, analyzed by sulforhodamine B (SRB) assay after 48 h treatment with 3.12–50 µM SLMP53-2. Data are mean ± SEM ( n = 5); * p < 0.05, extra sum-of-squares F test. ( B ) IC 50 values of SLMP53-2 and APR-246 in HuH-7 and HCC1419 cells were determined by SRB assay after 48 h treatment with 3.12–50 µM SLMP53-2 or APR-246. Data are mean ± SEM ( n = 5); * p < 0.05, two-way ANOVA with Sidak’s multiple comparison test. ( C ) Effect of SLMP53-2 in HuH-7 cell colony formation, analyzed after 14 days incubation with SLMP53-2; a representative experiment is shown. Data are mean ± SEM ( n = 5); values significantly different from DMSO: * p < 0.05, one-way ANOVA with Dunnett’s multiple comparison test. ( D ) Levels of γH2AX in HuH-7 cells treated with SLMP53-2; 50 µM etoposide was used as a positive control (PC). ( E ) Levels of mutp53 phosphorylation at Ser15 in HuH-7 cells treated with 14 µM SLMP53-2. In ( D , E ), immunoblots represent one of three independent experiments; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. ( F ) Top enriched biological pathways grouped by broad categories based on Ingenuity Pathway Analysis (IPA) starting from the dataset of differentially expressed genes (DEGs) from HuH-7 cells treated with 28 µM SLMP53-2. The number of features for each functional annotation is given in parenthesis. The score combines the log10 p -value and predicted pathway activation or repression status of the corresponding pathway/process, respectively for positive and negative score. The different colors correspond to the different functional annotation categories. ( G ) Top scoring upstream regulators inferred from the same gene expression dataset. The score is the log10 p -value of the predicted activation status. ( H ) Gene expression changes of NUPR1 (blue) and ATF4 (yellow) target genes in SLMP53-2-treated HuH-7 cells.

    Article Snippet: Human non-small cell lung carcinoma NCI-H1299, breast ductal carcinoma HCC1419, and non-tumorigenic foreskin fibroblast HFF-1 cell lines were purchased from ATCC (Rockville, MD, USA).

    Techniques: Expressing, Concentration Assay, Sulforhodamine B Assay, Incubation, Positive Control, Western Blot, Functional Assay, Activation Assay

    A panel of 12 parental and derived BCCLs were tested for trastuzumab response. Cells were classified as sensitive (S) or resistant (R) by testing cell proliferation in the presence and absence of 15 µg/ml trastuzumab for 7 days. Response to trastuzumab was quantified by calculating the fold change in the growth rate (∆GR) of the treated cells relative to the non-treated cells. In all cases resistance was defined as a response of ≤ 1.2 in growth rate

    Journal: American Journal of Cancer Research

    Article Title: Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines

    doi:

    Figure Lengend Snippet: A panel of 12 parental and derived BCCLs were tested for trastuzumab response. Cells were classified as sensitive (S) or resistant (R) by testing cell proliferation in the presence and absence of 15 µg/ml trastuzumab for 7 days. Response to trastuzumab was quantified by calculating the fold change in the growth rate (∆GR) of the treated cells relative to the non-treated cells. In all cases resistance was defined as a response of ≤ 1.2 in growth rate

    Article Snippet: The cell lines AU-565 (CRL-2351) adenocarcinoma, BT-474 (HTB-20) ductal carcinoma, HCC1419 (CRL-2326) ductal carcinoma, HCC1569 (CRL-2330) metaplastic carcinoma, HCC1954 (CRL-2338) ductal carcinoma, MDA-MB-361 (HTB-27) adenocarcinoma, SK-BR-3 (HTB-30) adenocarcinoma, and UACC-812 (CRL-1897) ductal carcinoma were obtained from the American Type Culture Collection.

    Techniques: Derivative Assay

    Amplification signal of the HER2 gene as determined by FISH. BCCL that showed ratio > 2.0 and > 4 HER2 copies were labeled as amplified, and those cases with ratio < 2.0 and 4-6 HER2 copies were determined as equivocal. Heterogeneity was observed as the percentage of tumor cells with ratio < 2.0 and < 4 HER2 copies

    Journal: American Journal of Cancer Research

    Article Title: Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines

    doi:

    Figure Lengend Snippet: Amplification signal of the HER2 gene as determined by FISH. BCCL that showed ratio > 2.0 and > 4 HER2 copies were labeled as amplified, and those cases with ratio < 2.0 and 4-6 HER2 copies were determined as equivocal. Heterogeneity was observed as the percentage of tumor cells with ratio < 2.0 and < 4 HER2 copies

    Article Snippet: The cell lines AU-565 (CRL-2351) adenocarcinoma, BT-474 (HTB-20) ductal carcinoma, HCC1419 (CRL-2326) ductal carcinoma, HCC1569 (CRL-2330) metaplastic carcinoma, HCC1954 (CRL-2338) ductal carcinoma, MDA-MB-361 (HTB-27) adenocarcinoma, SK-BR-3 (HTB-30) adenocarcinoma, and UACC-812 (CRL-1897) ductal carcinoma were obtained from the American Type Culture Collection.

    Techniques: Amplification, Labeling